Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lenhoff

Showing results (371-380 of 398) with videos related to

Pageof 40
Sort By:
Journal of Virological Methods|July 19, 2008
Multiplexed molecular assay for rapid exclusion of foot-and-mouth diseaseRaymond J Lenhoff, Pejman Naraghi-Arani, James B Thissen, et al.
Inorganic Chemistry|February 7, 2013
Characterization of an amorphous iridium water-oxidation catalyst electrodeposited from organometallic precursorsJames D Blakemore, Michael W Mara, Maxwell N Kushner-Lenhoff, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel AgentsFiroozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
American Journal of Hematology|October 20, 2022
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMTYves Chalandon, Giulia Sbianchi, Luuk Gras, et al.
Bone Marrow Transplantation|November 12, 2024
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMatjaz Sever, Joanna Drozd-Sokolowska, Luuk Gras, et al.
Bone Marrow Transplantation|April 1, 2022
Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMTJuan-Carlos Hernández-Boluda, Arturo Pereira, Nienke Zinger, et al.
British Journal of Haematology|April 28, 2022
Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMTDonal P McLornan, Luuk Gras, Ivonne Martin, et al.
Haematologica|December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working PartyHolger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
European Journal of Haematology|February 13, 2021
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMTLaurent Garderet, Giulia Sbianchi, Simona Iacobelli, et al.
Bone Marrow Transplantation|July 26, 2020
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMTNico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, et al.
Pageof 40

Showing results (371-380 of 398) with videos related to

Sort By:
Pageof 40
Journal of Virological Methods|July 19, 2008
Multiplexed molecular assay for rapid exclusion of foot-and-mouth diseaseRaymond J Lenhoff, Pejman Naraghi-Arani, James B Thissen, et al.
Inorganic Chemistry|February 7, 2013
Characterization of an amorphous iridium water-oxidation catalyst electrodeposited from organometallic precursorsJames D Blakemore, Michael W Mara, Maxwell N Kushner-Lenhoff, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel AgentsFiroozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
American Journal of Hematology|October 20, 2022
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMTYves Chalandon, Giulia Sbianchi, Luuk Gras, et al.
Bone Marrow Transplantation|November 12, 2024
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMatjaz Sever, Joanna Drozd-Sokolowska, Luuk Gras, et al.
Bone Marrow Transplantation|April 1, 2022
Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMTJuan-Carlos Hernández-Boluda, Arturo Pereira, Nienke Zinger, et al.
British Journal of Haematology|April 28, 2022
Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMTDonal P McLornan, Luuk Gras, Ivonne Martin, et al.
Haematologica|December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working PartyHolger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
European Journal of Haematology|February 13, 2021
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMTLaurent Garderet, Giulia Sbianchi, Simona Iacobelli, et al.
Bone Marrow Transplantation|July 26, 2020
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMTNico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, et al.
Pageof 40